Physician profile
Kathleen Shorla Miller
NPI 1467923383
$8,922.39
in general payments reported to CMS, 2019-2025
47 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 98% of General Practice (Registered Nurse) providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,178 · 2022: $1,915 · 2023: $1,898 · 2024: $1,810 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,829.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,487.97 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $785.85 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Sanofi-Aventis U.S. LLC | $778.75 | 2021-2025 | |
| Novo Nordisk INC | $667.59 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $629.04 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $581.18 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $393.96 | 2021-2025 | Lokelma, Farxiga |
| Corcept Therapeutics | $346.84 | 2021-2025 | Korlym |
| Radius Health, INC. | $323.84 | 2023-2025 | Tymlos |
| Abbvie INC. | $280.85 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $265.94 | 2021-2025 | Gvoke Hypopen |
| Amgen INC. | $242.54 | 2021-2025 | Evenity, Prolia, Tepezza |
| Recordati_rare_diseases_inc. | $237.29 | 2023-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $232.70 | 2021-2023 | Nocdurna, Xyosted, Tlando |
| Medtronic, INC. | $178.73 | 2023-2025 | Minimed 780g |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $140.08 | 2024-2025 | Yorvipath |
| Mannkind Corporation | $124.74 | 2022-2024 | Afrezza |
| Novartis Pharmaceuticals Corporation | $117.10 | 2025 | |
| Beta Bionics, INC. | $105.23 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Cequr Corporation | $94.18 | 2023-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $91.92 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $89.30 | 2021-2023 | Unithroid |
| Sequel Med Tech, LLC | $76.78 | 2025 | Twiist |
| Merck Sharp & Dohme LLC | $66.25 | 2021-2023 | Steglatro |
| Verity Pharmaceuticals INC. | $49.28 | 2024 | Tlando |
| Almatica Pharma LLC | $41.45 | 2024 | Teriparatide |
| Becton, Dickinson and Company | $39.30 | 2022 | |
| Halozyme INC | $33.99 | 2023 | |
| Madrigal Pharmaceuticals | $32.86 | 2025 | Rezdiffra |
| Embecta Corp. | $31.90 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Insulet Corporation | $31.78 | 2022 | |
| Neurocrine Biosciences, INC. | $28.53 | 2025 | |
| Biogen, INC. | $25.98 | 2025 | Skyclarys |
| Alvogen INC | $25.93 | 2022 | |
| Averitas Pharma INC. | $22.82 | 2023 | Qutenza |
| Ibsa Pharma INC. | $22.78 | 2024 | Tirosint, Flector, Licart |
| Amarin Pharma, INC. | $21.48 | 2021 | |
| Kyowa Kirin, INC. | $20.95 | 2023 | Crysvita |
| Inspire Medical Systems, INC. | $20.52 | 2025 | Inspire |
| Zealand Pharma US, INC. | $19.33 | 2021 | |
| Horizon Therapeutics Plc | $19.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.32 | 2023 | Strensiq |
| Astellas Pharma US INC | $17.88 | 2024 | Veozah |
| Pfizer INC. | $15.96 | 2023 | |
| Nevro Corp. | $14.95 | 2023 | Senza |
| Acerus Pharmaceuticals Corporation | $14.69 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $14.06 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.